At The American Journal of Managed Care’s Institute for Value-Based Medicine event that took place this past October, speakers discussed the high cost of new therapeutics. A balance must be struck, according to Kevin Cohen, MD, of Optum Care, using data analytics to optimize care quality and […]
ICER Report Suggests Lower Price for Lecanemab Than Aduhelm
The Institute for Clinical and Economic Review (ICER) has issued a report evaluating the value and cost-effectiveness of two amyloid-targeted therapeutics for Alzheimer's disease. Biogen and Eisai’s lecanemab was deemed by the agency to be cost effective if priced between $9,000 and $21,000, whereas […]
ICER Releases Evidence Report Reviewing Multiple Sclerosis Therapeutics
The Institute for Clinical and Economic Review (ICER) has released a newly revised evidence report covering several therapies for multiple sclerosis, comparing their clinical efficacy and relative value. The treatments include five monoclonal antibody therapies and eight oral drugs. Although the […]
ICER Releases List of Top Drugs with Unsubstantiated Price Hikes in 2021
A new report published by the Institute for Clinical and Economic Review (ICER) lays out a list of the top 10 therapeutics that had unsupported price hikes last year. Among the top ten were several high-price drugs that contributed significantly to US drug spending. Seven of the top 10 list were […]
ICER Announces Plans to Assess Sickle Cell Gene Therapy
Two sickle cell gene therapies will be assessed for value and efficacy by the Institute for Clinical and Economic Review (ICER), according to an announcement today, November 23rd. The institute will investigate lovotibeglogene autotemcel (“lovo-cel”, bluebird bio) and exagamglogene autotemcel […]
Accession Digital Platform Hits 7-Year Development Milestone
Accession has announced that its digital platform pathwaypro® has hit 7 years of product development, completing a major goal set by the company 7 years ago. The platform allows healthcare organizations and decision-makers to model drug optimization and value-assessment. In a recent annual ranking […]
What’s the State of Market Access in Denmark After Five Years with the Danish Medicines Council?
Denmark established the Danish Medicines Council (DMC) back in 2017 to help make assessment of medicines faster, transparent, and more consistent. In a recent Amerisource Bergen article, Flemming Axelsen, MSC, looks back at the past five years of the DMC, explaining its successes, failures, and the […]
Call For Reviewers: ISPOR 2023 – Opens November 18th
ISPOR will shortly open up applications for peer-reviewers for its upcoming ISPOR 2023 conference. Nominees will review research abstract submissions to ensure that research presented at the conference will meet ISPOR’s high standards. Reviewers are required to be non-student members of ISPOR and […]
Global Pricing Innovations Launches GPI Horizon Platform for Value Assessment
Global Pricing Innovations (GPI) has announced the launch of its new GPI Horizon platform. GPI Horizon is an analytics-based tool to expedite value-assessment and price prediction across the entire life cycle to help drive market access and reduce payer risk. The program is part of GPI’s larger […]
PCOC 2022: AJMC Talks with Dr. Kashyap Patel About Value-Based Care
This year’s Patient-Centered Oncology Care 2022 saw several talks about defining value in oncology care, according to Dr. Kashyap Patel of Community Oncology Alliance and Carolina Blood and Cancer Care Associates. Patel spoke about this and other topics covered at the conference with the AJMC staff […]
